Last checked at 30 Dec 2016 14:31
30 December 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the 'Company")
Grant of Awards under Long Term Incentive Plan
Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, announces that, pursuant to the Company's Long Term Incentive Plan ("LTIP") the following conditional awards of shares of 0.1 pence each were made to Executive Directors at nominal cost of 0.1 pence each on 30 December 2016.
Executive Director | Number of Conditional shares awarded | Total conditional shares held under LTIPs |
Manuel Llobet | 1,690,000 | 3,380,000 |
Nick Wykeman | 422,500 | 422,500 |
The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the satisfaction of performance conditions which include an earnings growth test over a three year testing period to 30 June 2019 and share price growth over the 3 year plan cycle.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |
a)
| Name
| Manuel Llobet Nicolas Wykeman |
2
| Reason for the notification Grant of conditional awards of 0.1 pence each
| |
a)
| Position/status
| Manual Llobet - Chief Executive Office Nicolas Wykeman - Finance Director |
b)
| Initial notification /Amendment
| Initial notification |
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
a)
| Name
| ALLERGY THERAPEUTICS PLC |
b)
| LEI
| |
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
a)
| Description of the financial instrument, type of instrument
Identification code
| Conditional award of shares under the Company's Long Term Incentive Plan
|
b)
| Nature of the transaction
| |
c)
| Price(s) and volume(s)
|
1,690,000
|
d)
| Aggregated information - Aggregated volume - Price |
|
e)
| Date of the transaction
| 30 December 2016 |
f)
| Place of the transaction
| Outside a trading venue |
Name of authorised official of issuer responsible for making notification:
Allergy Therapeutics +44 (0) 1903 845 820 | |
Manuel Llobet, Chief Executive Officer | |
Nick Wykeman, Finance Director | |
Panmure Gordon +44 (0) 20 7886 2500 Freddy Crossley / Duncan Monteith, Corporate Finance Tom Salvesen, Corporate Broking
| |
Consilium Strategic Communications +44 20 3709 5700 Mary-Jane Elliott / Ivar Milligan allergytherapeutics@consilium-comms.com
|
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.